Forest's Saunders ropes 2nd major sale, boosts personal brand in Actavis deal
This article was originally published in Scrip
Forest Laboratories president and CEO Brent Saunders has positioned himself as a most-wanted man in the biopharma industry with his second multibillion-dollar sale of a specialty pharmaceutical company in less than a year.
You may also be interested in...
Allergan generated enough cash flow in the first quarter to justify increased spending to develop and promote new products in 2017 – reinvesting because it can, not necessarily because it has to.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.